Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ovarian Cancer:

Targeted therapy of ovarian cancer including immune check point inhibitor. Kim JY et al. Korean J Intern Med. (2017)

Real-world evidence in the treatment of ovarian cancer. Eisenhauer EA et al. Ann Oncol. (2017)

Ovarian cancer stem cells more questions than answers. Ottevanger PB et al. Semin Cancer Biol. (2017)

Search results

Items: 1 to 20 of 109071

1.

Childhood Extracranial Germ Cell Tumors Treatment (PDQ®): Patient Version.

PDQ Pediatric Treatment Editorial Board.

PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-.
2019 Jan 15.

2.

TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions.

Tokunaga H, Shimada M, Ishikawa M, Yaegashi N.

Jpn J Clin Oncol. 2019 Jan 22. doi: 10.1093/jjco/hyy206. [Epub ahead of print]

PMID:
30668753
3.

The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.

Duran GE, Sikic BI.

PLoS One. 2019 Jan 22;14(1):e0210879. doi: 10.1371/journal.pone.0210879. eCollection 2019.

PMID:
30668583
4.

Diagnostic value of derived neutrophil-to-lymphocyte ratio in patients with ovarian cancer.

Wu YY, Qin YY, Qin JQ, Zhang X, Lin FQ.

J Clin Lab Anal. 2019 Jan 21:e22833. doi: 10.1002/jcla.22833. [Epub ahead of print]

PMID:
30666724
5.

Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.

Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, You D, Yi T, Wang P, Zhao X.

Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32143. [Epub ahead of print]

PMID:
30666631
6.

Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer.

Timmermans M, Sonke GS, Van de Vijver KK, Ottevanger PB, Nijman HW, van der Aa MA, Kruitwagen RFPM.

Int J Gynecol Cancer. 2019 Jan 21. pii: ijgc-2018-000100. doi: 10.1136/ijgc-2018-000100. [Epub ahead of print]

PMID:
30665898
7.

Secondary hematologic malignancies with poly adenosine diphosphate ribose polymerase inhibitors: Is the buzz real? -Insights from a meta-analysis of phase 3 randomized controlled trials.

Ball S, Sultan A, Zaw MH, Thein KZ.

J Geriatr Oncol. 2019 Jan 18. pii: S1879-4068(18)30405-3. doi: 10.1016/j.jgo.2019.01.008. [Epub ahead of print] No abstract available.

PMID:
30665875
8.

Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex.

Wang X, Peng J, Yang Z, Zhou PJ, An N, Wei L, Zhu HH, Lu J, Fang YX, Gao WQ.

J Exp Clin Cancer Res. 2019 Jan 21;38(1):27. doi: 10.1186/s13046-019-1025-2.

PMID:
30665442
9.

Self-Care Behaviors of Ovarian Cancer Patients Before Their Diagnosis: Proof-of-Concept Study.

Flanagan JM, Skrobanski H, Shi X, Hirst Y.

JMIR Cancer. 2019 Jan 17;5(1):e10447. doi: 10.2196/10447.

PMID:
30664464
10.

Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFR‑Akt pathway.

Zhang Y, Tao L, Fan LX, Huang K, Luo HM, Ge H, Wang X, Wang Q.

Mol Med Rep. 2019 Jan 17. doi: 10.3892/mmr.2019.9876. [Epub ahead of print]

PMID:
30664215
11.
12.

Isochamanetin is a Selective Inhibitor for CyclinD1 in SKOV3 Cell Lines.

Swarnalatha Y, Vidhya VG, Murugan A.

Nutr Cancer. 2019 Jan 19:1-11. doi: 10.1080/01635581.2018.1559933. [Epub ahead of print]

PMID:
30663403
13.

[THE PROLIFERATIVE EFFECT OF DENDRITIC CELLS IN OVARIAN CANCER AND THE RELATIONSHIP WITH THE IGF SIGNALING PATHWAY].

Alemi Yahya M, Meisel Sharon S, Hantisteanu S, Hallak M, Werner H, Bruchim I.

Harefuah. 2019 Jan;158(1):30-34. Hebrew.

PMID:
30663290
14.

Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials.

Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L.

Cancer Sci. 2019 Jan 21. doi: 10.1111/cas.13947. [Epub ahead of print]

PMID:
30663191
15.

The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI.

Xing F, Wang S, Zhou J.

Mol Ther Oncolytics. 2018 Dec 8;12:9-15. doi: 10.1016/j.omto.2018.12.002. eCollection 2019 Mar 29.

PMID:
30662936
16.

High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome.

Ma W, Duan H, Zhang R, Wang X, Xu H, Zhou Q, Zhang L.

J Cancer. 2019 Jan 1;10(1):267-276. doi: 10.7150/jca.27507. eCollection 2019.

PMID:
30662547
17.

Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer- A study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO).

Bhatt A, Sinukumar S, Mehta S, Damodaran D, Zaveri S, Kammar P, Mishra S, Parikh L, Ranade R, Penumadu P, Rajan F.

Eur J Surg Oncol. 2019 Jan 9. pii: S0748-7983(19)30009-5. doi: 10.1016/j.ejso.2019.01.009. [Epub ahead of print]

PMID:
30661922
18.

Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.

Chartron E, Theillet C, Guiu S, Jacot W.

Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5. Review.

PMID:
30661659
19.

Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.

Jabaley T, Underhill-Blazey ML, Berry DL.

J Cancer Educ. 2019 Jan 19. doi: 10.1007/s13187-019-1470-9. [Epub ahead of print]

PMID:
30661232
20.

Survival Impact of Optimal Surgical Cytoreduction in Recurrent Epithelial Ovarian Cancer with Brain Metastasis.

Keskin S, Küçücük S, Ak N, Atalar B, Sarı M, Sozen H, Ibis K, Topuz S, Saip P.

Oncol Res Treat. 2019 Jan 19;42(3). doi: 10.1159/000494334. [Epub ahead of print]

PMID:
30661076

Supplemental Content

Loading ...
Support Center